Ambrose Allison sold $3K of UPB
Ambrose Allison (General Counsel) sold 477 shares of Upstream Bio, Inc. (UPB) at $6.10 on 2026-06-16.
How this was made
The 30-second read
Why it matters
This provides incremental transparency on insider activity but does not include any new clinical, financial, regulatory, or deal catalyst for UPB.
Market read
Traders may monitor insider activity, but the disclosure alone is unlikely to drive a sustained repricing without corroborating company-specific news.
What to watch
The text doesn’t state whether the sale was part of compensation, tax planning, or other personal liquidity needs; also, the disclosed size is relatively small versus typical institutional flows.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for Upstream Bio, Inc. (UPB).
Ticker impact
Upstream Bio’s general counsel Ambrose Allison sold 477 shares in an open-market transaction at $6.10/share, per SEC Form 4 filed June 17.
Low near-term impact; any reaction is likely muted unless accompanied by other material company news.
The filing is a small, officer-level open-market sale with no 10b5-1 plan and no accompanying operational/regulatory catalyst in the text.
Market effects
No sector-level read-through; this is a single-company insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
The sale may be unrelated to company outlook (e.g., tax/portfolio rebalancing), so it may not warrant a bearish trade.
Key entities
- issuerUpstream Bio, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderAmbrose Allison
General Counsel who sold 477 shares at $6.10/share.
